» Articles » PMID: 18752564

Animal Models of NASH: Getting Both Pathology and Metabolic Context Right

Overview
Specialty Gastroenterology
Date 2008 Aug 30
PMID 18752564
Citations 148
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrhosis and end-stage liver disease. The main risk factors for NAFLD/NASH are the metabolic abnormalities commonly observed in metabolic syndrome: insulin resistance, visceral obesity, dyslipidemia and altered adipokine profile. At present, the causes of progression from NAFLD to NASH remain poorly defined, and research in this area has been limited by the availability of suitable animal models of this disease. In the past, the main models used to investigate the pathogenesis of steatohepatitis have either failed to reproduce the full spectrum of liver pathology that characterizes human NASH, or the liver pathology has developed in a metabolic context that is not representative of the human condition. In the last few years, a number of models have been described in which the full spectrum of liver pathology develops in an appropriate metabolic context. In general, the underlying cause of metabolic defects in these models is chronic caloric overconsumption, also known as overnutrition. Overnutrition has been achieved in a number of different ways, including forced feeding, administration of high-fat diets, the use of genetically hyperphagic animals, or a combination of these approaches. The purpose of the present review is to critique the liver pathology and metabolic abnormalities present in currently available animal models of NASH, with particular focus on models described in approximately the last 5 years.

Citing Articles

Enhancing the Therapeutic Efficacy of Berberine and Quercetin Through Salt Formulation for Liver Fibrosis Treatment.

Cheng Y, Yu H, Yang S, Tian X, Zhao M, Ren L Int J Mol Sci. 2025; 26(5).

PMID: 40076811 PMC: 11899775. DOI: 10.3390/ijms26052193.


Macrophage-Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis.

Su T, He Y, Wang M, Zhou H, Huang Y, Ye M Adv Sci (Weinh). 2024; 11(42):e2406500.

PMID: 39279458 PMC: 11558151. DOI: 10.1002/advs.202406500.


Emerging Insights into the Role of BDNF on Health and Disease in Periphery.

Ichimura-Shimizu M, Kurrey K, Miyata M, Dezawa T, Tsuneyama K, Kojima M Biomolecules. 2024; 14(4).

PMID: 38672461 PMC: 11048455. DOI: 10.3390/biom14040444.


Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.

Diwan R, Gaytan S, Bhatt H, Pena-Zacarias J, Nurunnabi M Drug Deliv Transl Res. 2024; 14(10):2743-2770.

PMID: 38446352 DOI: 10.1007/s13346-024-01551-8.


Esculeogenin A, a Glycan from Tomato, Alleviates Nonalcoholic Fatty Liver Disease in Rats through Hypolipidemic, Antioxidant, and Anti-Inflammatory Effects.

Al Jadani J, Albadr N, Alshammari G, Almasri S, Alfayez F, Yahya M Nutrients. 2023; 15(22).

PMID: 38004149 PMC: 10675668. DOI: 10.3390/nu15224755.